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yocardial Structural Effects
f Aldosterone Receptor
ntagonism in Heart Failure*
ay N. Cohn, MD, FACC
inneapolis, Minnesota
he remarkable effectiveness of aldosterone receptor antag-
nists in reducing the mortality risk in patients with
dvanced heart failure (HF) (1) has led many to assume that
he aldosterone receptor is directly involved in the process of
eft ventricular (LV) remodeling, which seems to be a
ritical mediator of the progressive syndrome of HF (2,3).
his perception has been fed by preclinical evidence for
ldosterone-mediated myocardial fibrosis and remodeling
4,5). But persuasive evidence has been lacking from an
dequately controlled clinical trial to demonstrate that the
avorable effect of this therapy could be attributed to its
nti-remodeling effect rather than to another mechanism,
uch as an antiarrhythmic response to potassium retention.
urthermore, the interaction between aldosterone receptor
lockade and the other neurohormonal inhibitors used in
F has not been explored.
See page 591
The single-site clinical trial reported in this issue of the
ournal by investigators at the Prince of Wales Hospital in
ong Kong (6) seems to have at least in part filled this data
ap. Publication of this study should also remind investiga-
ors that a single-institution study can address important
uestions in a modest-sized clinical trial if it is properly
esigned and overseen for compliance.
So is the issue now resolved? Does aldosterone receptor
lockade inhibit LV remodeling? Is its effect independent of
he antiremodeling effect of angiotensin-converting enzyme
ACE) inhibitor, angiotensin receptor blocker (ARB), and
eta-blocker medications, which now constitute standard
herapy in the management of HF? To address these
uestions we must examine the protocol, the results, and the
nterpretation.
Editorials published in the Journal of American College of Cardiology reflect the views
f the authors and do not necessarily represent the views of JACC or the American
ollege of Cardiology.t
From the Cardiovascular Division, Department of Medicine, University of Min-
esota Medical School, Minneapolis, Minnesota.rotocol
o provide uniform background renin-angiotensin sys-
em (RAS) inhibition, the protocol required patients to
e receiving chronic ACE inhibitor therapy (dose not
pecified), which was discontinued at the time of ran-
omization and replaced with a modest dose of an ARB
candesartan 8 mg). Given the mandate for RAS inhib-
ting therapy in HF, the design of trials such as this is
lways a compromise. There can be no assurance, how-
ver, of stability of RAS inhibition and certainly no
ssurance that the candesartan effect was similar to the
rior ACE inhibitor effect. Although the population was
resumably Asian and thus possibly responsive to lower
oses of neurohormonal inhibitors, it is unlikely that the
ncontrolled prior ACE inhibitor or the prescribed
andesartan provided optimal inhibition of the RAS.
urthermore, in a trial as small as this one (48 patients),
ndividual variability in response could weaken the sig-
ificance of group comparisons. Indeed, although the
roup randomized to spironolactone did not differ sig-
ificantly at baseline from the group randomized to
lacebo, modestly greater initial LV remodeling in the
pironolactone arm could have influenced the subsequent
esponse to therapy.
esults
he use of magnetic resonance imaging to quantitate LV
tructural changes made it possible to identify a therapeutic
ffect in this modest-sized trial. Most impressive was the
rogressive decline over the 1-year follow-up in the end-
iastolic and end-systolic LV volumes. This apparent rever-
al of remodeling, which was accompanied by a significant
eduction of LV mass, certainly suggests that spironolactone
as exerted a myocardial structural effect. The fall in blood
ressure in the spironolactone-treated group could have
ontributed to the structural benefit, but other blood
ressure-lowering drugs do not necessarily cause regression
f remodeling in HF (7,8).
Whether the remodeling effect of spironolactone is inde-
endent of that associated with other HF therapies is
ifficult to establish. Approximately 70% of the patients
ere said to be treated with a beta-blocker drug, but the
ype, dose, and duration of such therapy is not provided.
eta-blocker drugs produce reverse remodeling effects sim-
lar to that observed in this study (9), and the ARB, valsartan—
lbeit in a higher dose—inhibits remodeling when added to a
eta-blocker drug (10). The recent A-HeFT (African-
merican Heart Failure Trial) study has demonstrated
urther regression of remodeling when a fixed-dose combi-
ation of isosorbide dinitrate and hydralazine is added to
AS blockade and beta-blocker therapy in HF (11). One-
alf of the patients in the current trial were being treated
ith a nitrate (dose not stated), and whether chronic oral
itrate therapy not accompanied by hydralazine can con-
ribute to regression of remodeling is unknown. The Hong
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Editorial Comment August 14, 2007:597–9ong trial is certainly too small to attempt stratification by
ackground therapy to explore possible differential re-
ponses. Thus, the data are consistent with an effect inde-
endent of other inhibitor effects, but the issue cannot be
ully resolved.
nterpretation
he evidence for regression of LV structural remodeling in
esponse to spironolactone in this small trial supports the
reclinical structural and clinical biomarker data suggesting
favorable effect on myocardial interstitium and collagen.
hese observations lend credence to the concept that the
avorable effect of aldosterone inhibition on cardiovascular
utcomes can at least in part be attributed to their properties
o inhibit structural remodeling.
Regression of remodeling in response to an aldosterone
eceptor blocker drug does not necessarily lead to the
onclusion that aldosterone mediates the remodeling pro-
ess. Aldosterone levels are not independently predictive of
urvival in HF (12), and the favorable effect of aldosterone
lockade does not seem to be dependent on elevated
irculating levels. Furthermore, aldosterone receptors are
nder the influence of other steroids that might contribute
o the adverse effects of receptor stimulation (13).
An important feature of this study is that it was con-
ucted in patients with mild-to-moderate HF. The original
ALES (Randomized Aldactone Evaluation Study) was
arried out in advanced class (III to IV) HF. The exclusion
f milder HF has led guidelines committees to limit their
ecommendation of spironolactone to management of such
dvanced HF, even though no one can seriously suggest that
lass III to IV HF is a different disease from class II HF.
eft ventricular remodeling is a biologic process that is
ndependent from symptoms that define clinical severity.
herefore, the data supporting a salutary remodeling effect
n mild-to-moderate HF should help to convince the
edical community that outcome benefit, although easier to
emonstrate in patients with a higher event rate, should be
pplicable to all patients with the disease process.
A word of caution is required in interpreting the magni-
ude of effect of spironolactone observed in this study. The
ong Kong study was by its design carried out in a
omogeneous population. I have long advocated for such
omogeneous studies (14) not to predict the effect in any
ingle future patient but to demonstrate therapeutic poten-
ial. Racial, ethnic, and geographic differences in disease
echanisms, frequency, severity, and therapeutic response
lague efforts to apply large megatrial data to individual
atient care. Whether genetic or environmental factors drive
hese differences, their existence should dissuade us from
redicting benefits in one individual or population from a
tudy in a different population (15,16). Few large studies
ave examined outcome or biologic intermediate data in
sian populations. Therefore, these data from Hong Kong
hould encourage us about therapeutic potential but not
1ecessarily inform us about the magnitude of therapeutic
fficacy in a different population.
Magnetic resonance imaging certainly provides accurate
uantitation of LV structure. But global changes in chamber
olume and wall mass, as identified in the present study, are
robably only surrogates for the cellular and interstitial
hanges that likely are directly responsible for a favorable
ffect of drugs on the course of HF. Whether the unmea-
ured cellular effects of spironolactone differ from those of
CE inhibitor drugs, ARBs, beta-blocker drugs, and nitric
xide donors remains unknown. Knowledge of these cellular
ffects might allow us to use this array of drugs more
ationally, perhaps on the basis of the specific cellular and
nterstitial abnormalities in an individual patient. Such
olecular and cellular features might explain the apparent
opulation difference identified in diverse populations. The
ata from this small trial emphasize how valuable it would
e to demand that large trials attempt to correlate outcome
ffects with cardiac structural changes that could eventually
erve as more precise markers for efficacy (17).
eprint requests and correspondence: Dr. Jay N. Cohn, Cardio-
ascular Division, Mayo Mail Code 508, University of Minnesota
edical School, 420 Delaware Street SE, Minneapolis, Minnesota
5455. E-mail: cohnx001@umn.edu.
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